Table 4.

Multiple linear regression analysis of the 52-week changes in liver chemistries on histologic improvement, controlling for treatment group, baseline liver chemistries, age, sex, and BMI z-score

	β	95% CI	P
Outcome: Δ ALT (52-week-BL, U/L)
Histologic improvement (yes vs. no)	−29.9	−51.3, −8.5	0.006
Treatment group (Cyst vs. Plbo)	−20.4	−39.4, −1.3	0.04
Baseline ALT (U/L)	−0.5	−0.6, −0.4	<0.001
Baseline age (years)	−0.01	−3.6, 3.6	1.00
Sex (male vs. female)	−10.6	−31.0, 9.9	0.31
Baseline BMI z-score	33.3	12.1, 54.4	0.002
52-week change in BMI z-score	61.3	17.3, 105.4	0.007
Intercept	−11.8
Outcome: Δ AST (52-week-BL, U/L)
Histologic improvement (yes vs. no)	−10.8	−22.7, 1.2	0.08
Treatment group (Cyst vs. Plbo)	−13.6	−24.3, −2.8	0.01
Baseline AST (U/L)	−0.6	−0.7, −0.4	<0.001
Baseline age (years)	−0.8	−2.8, 1.2	0.42
Sex (male vs. female)	−7.8	−19.3, 3.7	0.18
Baseline BMI z-score	15.3	3.4, 27.1	0.01
52-week change in BMI z-score	26.2	1.5, 50.9	0.04
Intercept	14.2
Outcome: Δ GGT (52-week-BL, U/L)
Histologic improvement (yes vs. no)	−12.8	−18.9, −6.6	<0.001
Treatment group (Cyst vs. Plbo)	−6.1	−11.5, −0.6	0.03
Baseline GGT (U/L)	−0.3	−0.4, −0.2	<0.001
Baseline age (years)	0.7	−0.3, 1.8	0.17
Sex (male vs. female)	0.3	−5.6, 6.2	0.92
Baseline BMI z-score	3.5	−2.7, 9.7	0.27
52-week change in BMI z-score	14.0	1.3, 26.8	0.03
Intercept	−3.4